Magazine Article | November 1, 2023

How Prioritizing OpEx Can Raise Sinking Biopharma Valuations

Source: Life Science Leader

By Kelly Smeltzer

The life sciences industry, composed of pharmaceuticals, biotechnology, and medical devices, advances healthcare to improve the quality of life for people worldwide. However, as investment in the life sciences industry decreases, young companies struggle to keep the lights on. Young companies may overcome these challenges by implementing operational excellence (OpEx) early on in drug development rather than waiting until manufacturing startup. In doing so, they maximize their chances of high valuation and, in turn, robust investment and financial success.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader